Validation studies conducted in two independent MM cohorts identified commonly deregulated genes associated with Erk1/2i + CDK4/6i treatment: SNRPB, SLC25A5, and MAPKAPK2. SNRPB is part of both pre-catalytic and activated spliceosome complexes. Here, MAPK3 is linked to Miyoshi myopathy.